Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

Technology appraisal guidance
Reference number: TA814
Published: 03 August 2022

History

Final draft guidance

Final draft guidance
Final appraisal document (PDF 172 KB)

Published:

29 June 2022
Committee papers (PDF 1.08 MB)

Published:

29 June 2022
Public committee slides (PDF 1.63 MB)

Published:

29 June 2022

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) (PDF 300 KB)

Published:

08 April 2022
Appraisal consultation document (online commenting)
Committee papers (PDF 15.52 MB)

Published:

08 April 2022
Public committee slides (PDF 1.65 MB)

Published:

08 April 2022

Assessment report sent for information

Final protocol (PDF 862 KB)

Published:

07 January 2022

Invitation to participate

Equality impact assessment (Scoping) (PDF 131 KB)

Published:

05 August 2021
Final protocol (PDF 862 KB)

Published:

05 August 2021
Final stakeholder list (PDF 182 KB)

Published:

05 August 2021
Final scope (PDF 225 KB)

Published:

05 August 2021